Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
latozinemab (GSK4527223) / GSK
INFRONT-3, NCT04374136 / 2019-004066-18: A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia	Active, not recruiting	3	110	Europe, Canada, US, RoW	AL001, Placebo, Open label - AL001	Alector Inc., GlaxoSmithKline	Frontotemporal Dementia	09/25	08/27
NCT06111014: Continuation Study for Latozinemab	Enrolling by invitation	3	35	Europe, Canada, US	Latozinemab, AL001	Alector Inc., GlaxoSmithKline	Neurodegenerative Diseases	07/27	11/27
NCT05053035: A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS	Terminated	2	5	US	AL001, Placebo	Alector Inc.	Amyotrophic Lateral Sclerosis	10/22	10/22
INFRONT-2, NCT03987295 / 2019-000138-20: A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients	Completed	2	33	Europe, Canada, US	AL001	Alector Inc., GlaxoSmithKline	Frontotemporal Dementia	06/24	06/24